Anti-TIF1γ antibody-positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers
© 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology..
We report a case of anti-transcriptional intermediary factor 1γ (TIF1γ) antibody-positive dermatomyositis following durvalumab treatment. The patient was successfully treated with pulse steroid therapy, high-dose intravenous immunoglobulin (IVIg), and tacrolimus. Durvalumab may induce dermatomyositis, and early diagnosis and aggressive therapy are crucial to prevent severe dermatomyositis, which is potentially treatable.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Respirology case reports - 9(2021), 4 vom: 17. Apr., Seite e00736 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Imai, Ryosuke [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 31.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/rcr2.736 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM323332404 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM323332404 | ||
| 003 | DE-627 | ||
| 005 | 20240331233124.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/rcr2.736 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1358.xml |
| 035 | |a (DE-627)NLM323332404 | ||
| 035 | |a (NLM)33777398 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Imai, Ryosuke |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-TIF1γ antibody-positive dermatomyositis associated with durvalumab administration in a patient with lung and oesophageal cancers |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 31.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. | ||
| 520 | |a We report a case of anti-transcriptional intermediary factor 1γ (TIF1γ) antibody-positive dermatomyositis following durvalumab treatment. The patient was successfully treated with pulse steroid therapy, high-dose intravenous immunoglobulin (IVIg), and tacrolimus. Durvalumab may induce dermatomyositis, and early diagnosis and aggressive therapy are crucial to prevent severe dermatomyositis, which is potentially treatable | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Dermatomyositis | |
| 650 | 4 | |a durvalumab | |
| 650 | 4 | |a immune checkpoint inhibitor | |
| 650 | 4 | |a intravenous immunoglobulin | |
| 700 | 1 | |a Ikemura, Sumie |e verfasserin |4 aut | |
| 700 | 1 | |a Jinta, Torahiko |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respirology case reports |d 2013 |g 9(2021), 4 vom: 17. Apr., Seite e00736 |w (DE-627)NLM244269440 |x 2051-3380 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:4 |g day:17 |g month:04 |g pages:e00736 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/rcr2.736 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 4 |b 17 |c 04 |h e00736 | ||